University of Texas Southwestern Medical Center Researcher Reports on Findings in Multiple Sclerosis (Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series).

Předmět:	CNS demyelinating autoimmune diseases NEUROLOGICAL disorders DEMYELINATION IMMUNOSUPPRESSIVE agents MULTIPLE sclerosis
Zdroj:	Drug Week; 12/10/2024, p4167-4167, 1p
Abstrakt:	A recent study conducted at the University of Texas Southwestern Medical Center examined the clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis (MS) patients. The study found that individuals who transitioned from the brand-name drug Gilenya to generic fingolimod experienced disease advancement and elevated absolute lymphocyte counts (ALC). Testing revealed that some generic fingolimod products had lower than expected levels of the active ingredient, potentially leading to increased disease activity and the risk of disease rebound. This research highlights the importance of ensuring the potency and quality of generic specialty disease modifying therapies for MS treatment. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu